Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XMT-1522 |
Synonyms | |
Therapy Description |
XMT-1522 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeted antibody linked to auristatin, which delivers the cytotoxic agent to Erbb2 (Her2)-expressing tumor cells, potentially resulting in decreased tumor growth (PMID: 31292166). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XMT-1522 | XMT1522|XMT 1522 | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 | XMT-1522 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeted antibody linked to auristatin, which delivers the cytotoxic agent to Erbb2 (Her2)-expressing tumor cells, potentially resulting in decreased tumor growth (PMID: 31292166). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02952729 | Phase I | XMT-1522 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | Completed | USA | 0 |